Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
Title | Nodus |
Description | Developing next generation DDR targeting Nodus Oncology is developing first and best-in-class molecules inhibiting novel targets within the DNA damage response and replication stress |
Keywords | N/A |
WebSite | nodusoncology.com |
Host IP | 77.72.0.74 |
Location | United Kingdom |
Site | Rank |
US$1,124
Last updated: 2023-05-19 07:14:32
nodusoncology.com has Semrush global rank of 0. nodusoncology.com has an estimated worth of US$ 1,124, based on its estimated Ads revenue. nodusoncology.com receives approximately 129 unique visitors each day. Its web server is located in United Kingdom, with IP address 77.72.0.74. According to SiteAdvisor, nodusoncology.com is safe to visit. |
Purchase/Sale Value | US$1,124 |
Daily Ads Revenue | US$1 |
Monthly Ads Revenue | US$31 |
Yearly Ads Revenue | US$373 |
Daily Unique Visitors | 8 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
nodusoncology.com. | A | 14400 | IP: 77.72.0.74 |
nodusoncology.com. | NS | 14400 | NS Record: ns2.123-reg.co.uk. |
nodusoncology.com. | NS | 14400 | NS Record: ns.123-reg.co.uk. |
nodusoncology.com. | MX | 14400 | MX Record: 30 nodusoncology-com.mail.protection.outlook.com. |
nodusoncology.com. | TXT | 14400 | TXT Record: MS=ms13191270 |
nodusoncology.com. | TXT | 14400 | TXT Record: v=spf1 include:spf.protection.outlook.com -all |
Main menu Mission Team Investors Press Releases Partnerships Contact Developing next generation DDR targeting therapies Inducing tumour cell death by exploiting genomic instability and replication stress Our Mission Nodus Oncology is developing first and best-in-class molecules inhibiting novel targets within the DNA damage response and replication stress response. Supported by most recent scientific advances, we are developing the next wave of cancer therapeutics in the DNA damage response (DDR) area. Founded by Cumulus Oncology and in partnership with the Lead Discovery Centre, Nodus Oncology is developing an innovative portfolio focused on synthetic lethality and collateral vulnerabilities in molecularly defined cancer patient populations. Our Team A mix of extensive scientific expertise and experienced commercial strategy to develop an ambitious start up with several development programmes to bring innovative drugs to patients. Ian Waddell PhD Chief Executive Officer Research |
HTTP/1.1 301 Moved Permanently Connection: Keep-Alive Keep-Alive: timeout=5, max=100 date: Sun, 11 Sep 2022 08:54:30 GMT server: LiteSpeed location: https://nodusoncology.com/ vary: User-Agent HTTP/2 200 content-type: text/html last-modified: Thu, 08 Sep 2022 05:26:40 GMT accept-ranges: bytes content-length: 21551 date: Sun, 11 Sep 2022 08:54:30 GMT server: LiteSpeed vary: User-Agent,User-Agent alt-svc: h3=":443"; ma=2592000, h3-29=":443"; ma=2592000, h3-Q050=":443"; ma=2592000, h3-Q046=":443"; ma=2592000, h3-Q043=":443"; ma=2592000, quic=":443"; ma=2592000; v="43,46" |
Domain Name: NODUSONCOLOGY.COM Registry Domain ID: 2380858200_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.123-reg.co.uk Registrar URL: http://www.meshdigital.com Updated Date: 2021-04-09T06:44:36Z Creation Date: 2019-04-16T08:00:15Z Registry Expiry Date: 2023-04-16T08:00:15Z Registrar: 123-Reg Limited Registrar IANA ID: 1515 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS.123-REG.CO.UK Name Server: NS2.123-REG.CO.UK DNSSEC: unsigned >>> Last update of whois database: 2022-09-11T08:58:27Z <<< |